Actively Recruiting
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
Led by Tongji Hospital · Updated on 2025-04-11
50
Participants Needed
1
Research Sites
379 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.
CONDITIONS
Official Title
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 2 years and younger than 16 years with no genetic diseases
- Newly diagnosed with mild-to-moderate Crohn's disease (PCDAI >10 and 40, SES-CD >3)
- No change in medication or dose at least 1 week prior to transplantation
- Agree to receive regular colonoscopy
You will not qualify if you...
- Treated with corticosteroids, methotrexate, thiopurines, or anti-TNF agents as first-line treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
B
Biao Zou, MD
CONTACT
S
Sainan Shu, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here